Tirzepatide + Retatrutide
Two drugs from the same class, sold in one vial, against the label of the one that is approved.
Tirzepatide is the approved weight loss drug sold as Mounjaro and Zepbound. Retatrutide is its stronger, unapproved successor. Both are made by the same company, both act on the same two receptors, and one vendor sells them premixed. The approved drug's own label says not to do this.
If one works, two should work harder.
The logic is simple addition. Tirzepatide produces substantial weight loss, retatrutide produces more, and someone who has plateaued on one reaches for the other on top.
It usually starts with a plateau. Weight loss on these drugs slows after the first year, and adding a second compound feels like the obvious lever to pull. Being able to buy both in one vial makes it feel sanctioned.
The problem is that these are not two different drugs doing two different jobs. They are two versions of one idea, from the same manufacturer, acting on the same two receptors. That is the opposite of the reasoning behind every stack worth considering.
Three benefits, and how well each one holds up.
The middle row is real, and it belongs to each drug taken on its own. Nothing supports the top row, and the approved drug's label argues against it.
Three questions, answered before anything else.
Three receptors, and two of them are shared.
Both drugs copy gut hormones that act on receptors in the pancreas, gut and brain. The table shows which receptors each one switches on.[3]
Two of the three rows are the same drug target hit twice. Only glucagon is new, and retatrutide already supplies it on its own.
So adding tirzepatide to retatrutide contributes nothing retatrutide lacks. Adding retatrutide to tirzepatide contributes glucagon, which is the one real difference, and it comes bundled with a second dose of the two receptors the first drug is already working.
Compare that with CagriSema, where the two compounds act on separate systems, GLP-1 and amylin. That is the structure a stack needs, and even there the combination delivered 88 percent of what simple addition predicted.
The approved drug's own instructions rule this out.
This is unusual on this site. Most stacks have no evidence either way. This one has a direct statement from the regulator and the manufacturer.
Retatrutide is a GLP-1 receptor agonist, alongside its GIP and glucagon activity. The warning applies to it directly.
There is an irony in who wrote that warning. Eli Lilly makes tirzepatide and is developing retatrutide. The company telling doctors not to combine its approved drug with any GLP-1 agonist is the same company whose next GLP-1 agonist is being sold premixed with it.
Lilly has also published an open letter stating that it does not promote its medicines outside their approved indications and that they should not be used for cosmetic weight loss.[2]
Both drugs make people sick in the same way.
Nausea, vomiting, diarrhoea and constipation are the defining side effects of this whole drug class, and they come from the receptors both compounds share.
In retatrutide's TRIUMPH-1 trial at the top dose, nausea hit 42.4 percent against 14.8 on placebo, and vomiting 25.3 against 4.8. About 11.3 percent stopped because of side effects.[4] Tirzepatide carries the same class of effects on its own label, including warnings about severe stomach problems.[2]
Doubling the receptors that cause nausea is the expected way to get more nausea. Nobody has measured the combined figures because nobody has run the trial, but the direction is not in much doubt.
Blood sugar is the other concern. Both lower it, and one warning source lists low blood sugar among the risks of combining two drugs in this class, especially for anyone also taking diabetes medication.[5] Retatrutide also raises heart rate by around 6.7 beats per minute at its top dose, more than tirzepatide does on its own.[4]
A second drug on a separate pathway.
The honest version of the idea behind this stack is to add something that works differently from the first drug. The evidence points one way.
Amylin compounds act on a separate fullness pathway, slowing how fast the stomach empties. CagriSema paired one with semaglutide and is the only stack on this site tested against each of its own parts. It reached 22.7 percent weight loss against 16.1 for semaglutide alone.
Grey-market sellers also pair cagrilintide with retatrutide, which has its own page and its own problems, chiefly a ratio far from the tested version. It is still a combination of two different mechanisms, which this one is not.
For someone on a plateau, the conversation with a prescriber is usually about dose, time and whether a switch between drugs makes sense, rather than about running two at once.
One premixed vial, and a price list with an error in it.
We track one in-stock listing selling the two together, at $185.00 for a 25 mg vial split 15 mg tirzepatide to 10 mg retatrutide.[6] A second listing combining semaglutide and tirzepatide shows no stock and states no amounts.
Tirzepatide on its own is in 156 in-stock single-compound listings, with a median price of $100.00.[6] The cheapest few are from a single vendor at prices that do not look real, including a 60 mg vial for $4.00. We are treating those as listing errors rather than prices, which is why this page quotes the median instead of the minimum.
Retatrutide starts at $32.48 across 225 listings.[6]
One approved drug, one unapproved, combined against the label.
Tirzepatide is approved in the United States as Mounjaro for type 2 diabetes and as Zepbound for chronic weight management and obstructive sleep apnoea with obesity.[1]
Retatrutide is approved nowhere. It has five positive Phase 3 trials, and Lilly plans to file for US approval in the first quarter of 2027.[4]
So this vial contains an unapproved drug mixed with an approved one, in a combination the approved drug's label rules out. Everything sold online as a research chemical is unapproved material regardless of which compounds are in it.
Anyone already taking tirzepatide on prescription and considering adding retatrutide has the clearest possible reason to raise it with the prescriber first.
What people ask about this stack
Can you take tirzepatide and retatrutide together?
The approved drug's label says no. The FDA's approval notice for Zepbound states it should not be used in combination with Mounjaro or a GLP-1 receptor agonist, and retatrutide is a GLP-1 receptor agonist. Lilly's prescribing materials say the same. No trial has tested the two together and no guideline supports it.
Why is combining them a problem?
Tirzepatide and retatrutide act on two of the same three receptors, GIP and GLP-1. Retatrutide adds glucagon, which tirzepatide does not touch. So combining them doubles up on the shared pair rather than adding a new mechanism. Those shared receptors are the ones behind the nausea, vomiting and digestive side effects the drug class is known for.
Who makes these two drugs?
Eli Lilly makes both. Tirzepatide is its approved drug, sold as Mounjaro and Zepbound, and retatrutide is its successor still in trials. The company whose label warns against combining tirzepatide with any GLP-1 agonist is the same company developing retatrutide, which is one.
What should someone on a plateau do instead?
Adding a drug that works on a separate pathway is the better-evidenced version of the idea. Amylin compounds such as cagrilintide act on a different fullness signal, and CagriSema, which paired one with semaglutide, is the only stack on this site tested against each of its parts. For someone on a prescribed drug, a plateau is a conversation with the prescriber about dose, time or switching.
Is the premixed vial worth buying?
The premixed vial combines two drugs the approved one's label says not to combine. We track one in-stock listing at $185.00 for 25 mg, split 15 mg tirzepatide to 10 mg retatrutide. A second listing pairing semaglutide with tirzepatide states no amounts and shows no stock.
How much weight does each drug cause on its own?
Tirzepatide reached 22.5 percent average weight loss in its SURMOUNT-1 trial. Retatrutide reached 28.3 percent over 80 weeks at the top dose in TRIUMPH-1, the largest result anyone has published. Those are separate trials of each drug alone. Compare against the other stacks.
What this page is built on
- 01U.S. Food and Drug Administration. FDA approves new medication for chronic weight management. Press announcement. States that Zepbound should not be used in combination with Mounjaro or a GLP-1 receptor agonist, and that the safety and effectiveness of coadministration with other weight management medications have not been established.
- 02Eli Lilly and Company. Zepbound prescribing and patient materials, and an open letter regarding the use of Mounjaro and Zepbound. Prescriber page. Source for Zepbound not being used with other tirzepatide-containing products or any GLP-1 receptor agonist medicine, for warnings about severe stomach problems, and for Lilly stating it does not promote use outside approved indications or for cosmetic weight loss.
- 03Receptor activity of the two compounds: tirzepatide acting on GIP and GLP-1, retatrutide on GIP, GLP-1 and glucagon, with the shared GIP and GLP-1 activity making combination largely redundant. See also Willard FS et al., tirzepatide as an imbalanced and biased dual GIP and GLP-1 receptor agonist, PMC7526454.
- 04Retatrutide Phase 3 programme and adverse events. TRIUMPH-1 NCT05929066, 28.3 percent weight loss at the top dose over 80 weeks. Adverse events against placebo: nausea 42.4 against 14.8 percent, vomiting 25.3 against 4.8, discontinuation 11.3 against 4.9. Heart rate rise of around 6.7 beats per minute. US filing planned for the first quarter of 2027.
- 05Clinical guidance on combining GLP-1 class drugs. Source for concurrent use of multiple drugs in the class not being recommended, and for listed risks including nausea, vomiting, diarrhoea and low blood sugar, especially in people taking diabetes medication.
- 06Peptide Decoding vendor pricing data, 21 September 2026. One in-stock premixed listing at $185.00 for 25 mg, composition 15 mg tirzepatide and 10 mg retatrutide. A second listing pairing semaglutide and tirzepatide with no stated amounts and no stock. Tirzepatide in 156 in-stock single-compound listings with a median of $100.00; the lowest listings, from a single vendor, include a 60 mg vial at $4.00 and are treated as listing errors. Retatrutide from $32.48 across 225 listings.